DexCom Inc. (DXCM) PT Set at $70.00 by Canaccord Genuity
DexCom Inc. (NASDAQ:DXCM) received a $70.00 target price from investment analysts at Canaccord Genuity in a research report issued on Monday. The brokerage currently has a a “buy” rating on the medical device company’s stock. Canaccord Genuity’s target price would indicate a potential downside of 2.18% from the stock’s current price.
Several other research analysts also recently commented on DXCM. B. Riley reiterated a “neutral” rating and issued a $84.00 target price on shares of DexCom in a report on Wednesday, November 2nd. Oppenheimer Holdings Inc. set a $84.00 target price on shares of DexCom and gave the stock a “hold” rating in a report on Wednesday, November 2nd. BTIG Research reiterated a “buy” rating and issued a $92.00 target price on shares of DexCom in a report on Thursday, August 4th. Wedbush reiterated an “outperform” rating and issued a $112.00 target price (up previously from $100.00) on shares of DexCom in a report on Wednesday, November 2nd. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $100.00 target price (up previously from $93.00) on shares of DexCom in a report on Thursday, August 4th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $92.07.
Shares of DexCom (NASDAQ:DXCM) opened at 71.53 on Monday. DexCom has a 1-year low of $47.92 and a 1-year high of $96.38. The company’s 50-day moving average is $77.37 and its 200 day moving average is $79.57. The firm’s market cap is $6.05 billion.
In other DexCom news, insider Terrance H. Gregg sold 10,740 shares of the business’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $95.29, for a total value of $1,023,414.60. Following the completion of the transaction, the insider now directly owns 451,486 shares of the company’s stock, valued at $43,022,100.94. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Steven Robert Pacelli sold 10,300 shares of the business’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $81.95, for a total transaction of $844,085.00. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of DexCom during the second quarter worth $134,000. Parametrica Management Ltd bought a new position in shares of DexCom during the second quarter worth $254,000. CIBC World Markets Inc. bought a new position in shares of DexCom during the second quarter worth $1,797,000. Westwood Management Corp IL increased its position in shares of DexCom by 108.3% in the second quarter. Westwood Management Corp IL now owns 25,000 shares of the medical device company’s stock worth $1,983,000 after buying an additional 13,000 shares in the last quarter. Finally, IBM Retirement Fund increased its position in shares of DexCom by 3.7% in the second quarter. IBM Retirement Fund now owns 8,303 shares of the medical device company’s stock worth $659,000 after buying an additional 297 shares in the last quarter. 96.22% of the stock is owned by institutional investors.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.